Intravenous Iron Therapy Market Size, Share, and Growth Forecast, 2026 - 2033

Intravenous Iron Therapy Market by Product Formulation (Ferric Carboxymaltose, Iron Isomaltoside/Ferric Derisomaltose, Others), Clinical Application (Chronic Kidney Disease/Dialysis-Associated Anemia, Heart Failure With Iron Deficiency, Others), End-user, Administration Protocol, and Regional Analysis for 2026 - 2033

ID: PMRREP27787
Calendar

October 2026

192 Pages

Author : Abhijeet Surwase

Intravenous Iron Therapy Market Size and Trends Analysis

The global intravenous iron therapy market size is likely to be valued at US$4.1 billion in 2026 and is expected to reach US$6.5 billion by 2033, growing at a CAGR of 6.8% between 2026 and 2033, driven by increasing use of intravenous iron to manage iron deficiency anemia associated with chronic kidney disease, heart failure, cancer treatment, and other chronic conditions.

High-dose formulations are improving treatment convenience by reducing the number of infusion sessions required for eligible patients. Growing recognition of iron deficiency across multiple specialties is creating opportunities beyond traditional dialysis settings. However, treatment costs, safety monitoring requirements, reimbursement limitations, and competition from lower-cost formulations will influence market expansion through 2033.

Key Industry Highlights

  • Leading Region: North America leads with an anticipated 51.6% of market revenue in 2026, supported by advanced hospital infrastructure, specialist nephrology services, and established use of high-dose intravenous iron formulations.
  • Fastest-growing Region: Asia Pacific is expanding rapidly due to improving diagnosis, healthcare infrastructure, and treatment access. China's reimbursement expansion for Ferinject's pediatric indication supports access for eligible patients.
  • Dominant Product Formulation: Ferric carboxymaltose leads product formulations, with an anticipated 47.3% revenue share, supported by high-dose administration and established brands such as Injectafer and Ferinject.
  • Leading Clinical Application: Chronic kidney disease and dialysis-associated anemia leads clinical applications, accounting for an anticipated 42.1% of market share.

intravenous-iron-therapy-market-2026-2033

See exactly what you're buying — Before you spend a dollar.

Get a free sample copy of our market report: data, tables, charts, research depth, analyst insights, and relevance of our research - all in hand before you commit.

DRO Analysis

Drivers - Growing Burden of Chronic Kidney Disease and Associated Anemia

Chronic kidney disease (CKD) is a significant source of demand for intravenous iron therapy because impaired kidney function can disrupt red blood cell production and contribute to anemia. The U.S. Centers for Disease Control and Prevention reported in 2024 that more than one in seven U.S. adults had CKD, with as many as nine in ten affected individuals unaware of their condition. The 2026 Kidney Disease: Improving Global Outcomes guideline updates recommendations for anemia management across nondialysis CKD, dialysis, and kidney transplantation.

These developments reinforce the importance of systematic anemia assessment and appropriate iron replacement in nephrology departments and dialysis facilities. Patients receiving dialysis may require repeated evaluation and treatment because of ongoing iron losses and the underlying effects of kidney disease. For manufacturers, established relationships with nephrologists, dialysis providers, and hospital purchasing organizations offer opportunities to maintain recurring demand. However, CKD prevalence does not directly translate into intravenous iron prescriptions because treatment depends on individual iron status, clinical assessment, and the suitability of therapy.

Expansion into Heart Failure and Other Clinical Applications

Intravenous iron therapy is increasingly relevant to clinical pathways beyond conventional iron deficiency anemia management. The American College of Cardiology's 2024 review describes guideline support for intravenous iron replacement in selected patients with heart failure with reduced ejection fraction and iron deficiency to improve functional status and quality of life. However, clinical evidence remains nuanced, and improvements in symptoms or functional capacity do not establish a consistent mortality benefit across every patient group.

This distinction creates opportunities for products supported by clear dosing instructions, established safety information, and clinical evidence relevant to specific patient populations. Wider adoption by cardiology services could diversify demand beyond renal care, while oncology, perioperative medicine, gastroenterology, and obstetrics provide additional potential treatment settings. Manufacturers can benefit from this diversification by developing evidence-based clinical education and strengthening relationships with specialists. Commercial growth will nevertheless depend on patient selection, treatment guidelines, reimbursement policies, and the ability of healthcare providers to identify iron deficiency accurately.

Restraint - Safety Monitoring, Treatment Costs, and Administration Requirements

Intravenous iron requires trained healthcare personnel, appropriate infusion facilities, and monitoring for adverse reactions. European regulatory guidance recommends observation during administration and for at least 30 minutes afterward because serious hypersensitivity reactions can occur with intravenous iron preparations. These requirements increase staffing and facility costs and may limit adoption in healthcare systems with constrained infusion capacity.

Safety considerations are particularly relevant to ferric carboxymaltose. On September 1, 2026, the U.S. Food and Drug Administration required a boxed warning for Injectafer concerning symptomatic hypophosphatemia, including recommendations for phosphate monitoring in specified circumstances. Such requirements can increase treatment costs and influence prescribing decisions, particularly when repeated courses are necessary. Healthcare providers must balance the convenience of high-dose formulations against acquisition costs, monitoring requirements, clinical suitability, and the availability of alternative preparations.

Opportunities - Broader Diagnosis and Treatment in Underserved Patient Populations

Persistent anemia creates an opportunity to expand access to appropriate diagnostic testing and iron replacement in emerging markets. The World Health Organization's 2025 estimates indicate that 30.7% of women aged 15-49 years experienced anemia in 2023, while anemia prevalence among pregnant women reached 35.5%. These figures describe anemia overall rather than confirmed iron deficiency and should not be interpreted as the immediately treatable population for intravenous iron.

The commercial opportunity lies in improving iron-status assessment and providing parenteral treatment when clinically indicated. India, Southeast Asia, and other emerging markets may offer opportunities through hospital procurement programs, local pharmaceutical manufacturing, public-private partnerships, and tiered pricing. Manufacturers can improve access by developing reliable distribution networks and offering products suited to different healthcare budgets. However, expansion will depend on diagnostic capacity, clinician training, reimbursement, regulatory approval, and the availability of facilities equipped to administer intravenous medicines safely.

High-Dose Formulations and Outpatient Infusion Models

High-dose formulations can reduce the number of appointments needed to replace a patient's iron deficit, supporting more efficient outpatient treatment. U.S. prescribing information for ferric derisomaltose, marketed as Monoferric, permits a 1,000 mg infusion for adults weighing at least 50 kg, subject to the approved indication and prescribing instructions.

This dosing profile illustrates the operational appeal of formulations that deliver larger replacement doses in a single visit. Manufacturers can build on this advantage through partnerships with hospital outpatient departments, specialty infusion centers, and appropriate community-based services. Investments in convenient administration, predictable supply, clinician education, and safety monitoring may improve treatment completion while helping healthcare providers manage capacity. The commercial benefit will depend on total treatment costs, clinical suitability, product labeling, and reimbursement rather than dose size alone.

Category-wise Analysis

Product Formulation Insights

Ferric carboxymaltose is the leading formulation, with an anticipated share of approximately 47.3% of the market share in 2026. Its position reflects high-dose administration, established use in iron deficiency anemia, and convenience in hospital and outpatient settings. Examples include Injectafer in the United States and Ferinject in several international markets. The formulation is also used in selected patients with heart failure and other approved indications. However, product selection depends on clinical suitability, safety considerations, prescribing guidelines, and treatment costs.

Ferric derisomaltose is the fastest-growing formulation. Marketed as Monoferric in the United States and Monofer in other markets, it supports high-dose administration, including a 1,000 mg infusion for eligible adults weighing at least 50 kg under U.S. labeling. This can reduce repeat visits and improve outpatient infusion efficiency. Iron sucrose remains widely used in dialysis settings, while ferumoxytol, ferric gluconate, and iron dextran serve additional clinical needs. Competition will depend on pricing, product availability, clinical familiarity, and safety monitoring requirements, particularly following the September 2026 U.S. regulatory action concerning hypophosphatemia associated with ferric carboxymaltose.

Clinical Application Insights

Chronic kidney disease and dialysis-associated anemia lead the clinical application segment, with an anticipated share of approximately 42.1% of global market revenue in 2026. Patients receiving dialysis may experience ongoing iron losses and impaired red blood cell production, creating recurring demand for iron replacement. Intravenous therapy fits established dialysis workflows, allowing healthcare teams to coordinate treatment with routine monitoring. The 2026 kidney disease anemia guideline update reinforces the importance of individualized, evidence-based treatment. For suppliers, this segment offers recurring demand through relationships with nephrologists, dialysis providers, and hospital procurement teams.

Heart failure with iron deficiency is the fastest-growing application, with a projected CAGR of approximately 10.0% through 2031. Clinical guidance supports intravenous iron for selected patients with reduced ejection fraction and iron deficiency to improve functional status and quality of life. For example, ferric carboxymaltose and ferric derisomaltose are used in relevant approved markets for eligible patients. Other applications include chemotherapy-related anemia, nondialysis CKD, perioperative anemia, inflammatory bowel disease, and obstetric iron deficiency. Growth will depend on accurate diagnosis, clinical evidence, appropriate patient selection, and reimbursement, as treatment benefits and prescribing recommendations vary across indications.

intravenous-iron-therapy-market-outlook-by-product-formulation-2026-2033

Not every business fits the same mold. Your research shouldn't either.

Connect with the team for a customization and get a one-of-a-kind report scoped to your niche — The insights your competitors won't have access to.

Regional Insights

North America Intravenous Iron Therapy Market Trends

North America leads the intravenous iron therapy market, accounting for an anticipated 51.6% of global revenue. Established hospital networks, specialist nephrology services, and outpatient infusion facilities support demand across kidney disease, heart failure, and perioperative care.

U.S. Intravenous Iron Therapy Market Trends

The U.S. anchors regional sales through branded products such as Injectafer, Venofer, and Monoferric. The CDC reported in 2024 that more than one in seven U.S. adults had chronic kidney disease, supporting the importance of anemia assessment in kidney care, although CKD prevalence does not directly indicate eligibility for intravenous iron.

In September 2026, the FDA added a boxed warning to Injectafer labeling for symptomatic hypophosphatemia, recommending phosphate monitoring in specified circumstances. This development may increase monitoring requirements and influence treatment selection, strengthening the importance of safety protocols alongside dosing convenience.

Canada Intravenous Iron Therapy Market Trends

Canada contributes through public hospitals, specialist services, and provincial procurement systems. Access to products depends on provincial reimbursement and local treatment pathways. Competition between branded high-dose formulations and established iron sucrose products makes acquisition costs, infusion frequency, and monitoring requirements important considerations for healthcare providers.

Europe Intravenous Iron Therapy Market Trends

Europe represents an established market supported by national healthcare systems, specialist renal services, and hospital-based iron replacement. Germany and the United Kingdom illustrate how procurement structures, clinical guidance, and medicine costs influence product adoption.

Germany Intravenous Iron Therapy Market Trends

Germany's extensive hospital infrastructure supports intravenous iron use in renal, cardiac, and perioperative settings. Products such as Ferinject and Monofer provide high-dose treatment options, while iron sucrose remains relevant in established clinical pathways. Manufacturers must demonstrate reliable supply and clinical value in a market where hospitals consider both medicine costs and administration resources.

United Kingdom Intravenous Iron Therapy Market Trends

The National Health Service provides a substantial care network for managing iron deficiency across hospital and outpatient settings. Local formularies and procurement decisions influence product selection. In September 2026, the European Medicines Agency's safety committee began reviewing injectable iron medicines over hypophosphatemia and related bone complications. The review could affect monitoring practices and prescribing decisions across European markets, although final regulatory recommendations remain subject to assessment.

Asia Pacific Intravenous Iron Therapy Market Trends

Asia Pacific is the fastest-growing regional market, supported by expanding healthcare infrastructure, improved diagnostic capacity, and greater access to specialist treatment. China and India offer contrasting opportunities through reimbursement expansion and domestic pharmaceutical manufacturing.

China Intravenous Iron Therapy Market Trends

China's large hospital network and pharmaceutical sector support the expansion of intravenous iron access. Ferinject received Chinese marketing authorization in 2022, with its launch expected in 2023. CSL Vifor subsequently reported that the product's pediatric indication was included in China's National Reimbursement Drug List, illustrating how reimbursement decisions can expand access for eligible patients and support commercial growth.

Domestic procurement and affordability remain important. Suppliers need to navigate registration requirements, hospital purchasing practices, and reimbursement conditions to expand beyond major urban centers.

India Intravenous Iron Therapy Market Trends

India combines a substantial anemia burden with established domestic pharmaceutical manufacturing. Government data published in 2025 reported anemia among 67.1% of children and 59.1% of adolescent girls in the fifth National Family Health Survey. These figures concern anemia generally, not the population eligible for intravenous iron, but highlight the importance of appropriate diagnosis and treatment pathways.

Companies including Emcure, Lupin, and Intas participate in India's pharmaceutical market, where ferric carboxymaltose brands such as Orofer FCM provide options for eligible patients. Affordability, clinician awareness, hospital availability, and access to safe infusion facilities will influence adoption.

Across Asia Pacific, locally adapted pricing, dependable distribution, and clinical education are likely to be central to growth. High-dose formulations may reduce repeat visits, while lower-cost products remain important where healthcare budgets and patient affordability constrain treatment choices.

intravenous-iron-therapy-market-outlook-by-region-2026-2033

Competitive Landscape

The global intravenous iron therapy market combines established branded medicines with generic injectable products. CSL Vifor, American Regent and Daiichi Sankyo, Pharmacosmos, and Covis Pharma have identifiable positions through products such as Ferinject, Injectafer, Monoferric, and Feraheme. Iron sucrose and other established formulations also face competition from multiple suppliers. High-dose product convenience, regulatory approvals, clinical evidence, safety, pricing, and distribution capacity shape competitive positioning.

Market leaders compete through high-dose formulations, clinical evidence, regulatory approvals, geographic expansion, and reliable supply. Manufacturers of established products can strengthen their positions by improving treatment access and supporting appropriate monitoring. Generic suppliers compete on cost, manufacturing quality, tender access, and distribution. Emerging opportunities include partnerships with specialty infusion providers, local market licensing, and treatment pathways that reduce avoidable repeat visits.

Key Industry Developments:

  • In September 2026, the U.S. Food and Drug Administration approved a boxed warning for ferric carboxymaltose products, including Injectafer, concerning symptomatic hypophosphatemia.

Companies Covered in Intravenous Iron Therapy Market

  • CSL Vifor
  • American Regent, Inc.
  • Pharmacosmos A/S
  • Covis Pharma
  • Daiichi Sankyo Company, Limited
  • Sanofi
  • Fresenius Kabi
  • Hikma Pharmaceuticals
  • Sandoz
  • Viatris
  • Emcure Pharmaceuticals
  • Lupin Limited
  • Intas Pharmaceuticals
  • Zydus Lifesciences
  • Sun Pharmaceutical Industries
  • Rockwell Medical
Frequently Asked Questions

The global intravenous iron therapy market is valued at US$4.1 billion in 2026.

The intravenous iron therapy market is expected to reach US$6.5 billion by 2033.

Key trends include increasing adoption of high-dose formulations, expanding use in selected heart failure patients, greater emphasis on outpatient infusion efficiency, and enhanced safety monitoring.

Ferric carboxymaltose leads the product formulation segment, with an anticipated 47.3% revenue share. Chronic kidney disease and dialysis-associated anemia lead the clinical application segment.

The intravenous iron therapy market is projected to grow at a CAGR of 6.8% from 2026 to 2033.

Major players include CSL Vifor, Daiichi Sankyo / American Regent, Pharmacosmos A/S, Covis Pharma, and Emcure Pharmaceuticals.

UK

Corporate Office

Persistence Research & Consultancy Services Limited

Company Number : 15310893

Second Floor, 150 Fleet Street,London, EC4A 2DQ.

+44 203-837-5656
USA

Regional Office

Persistence Market Research

108 W 39th Street, Ste 1006,PMB2219, New York, NY 10018

+1 646-878-6329
India

Global Research centre

Persistence Market Research Private Limited

CIN : U74900PN2014PTC153163

6th Floor, Teerth Technospace, Teerth Realties, Office No. B- 604, Baner, Pune, Maharashtra 411045

Copyright © 2026 Persistence Market Research. All Rights Reserved

Connect With Us -